Rhythm Pharmaceuticals Reports First Quarter 2019 Financial Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Rhythm Pharmaceuticals Reports First Quarter 2019 Financial Results

Rhythm Pharmaceuticals (RYTM) Misses Q1 EPS by 8c

May 3, 2019 8:38 AM EDT

Rhythm Pharmaceuticals (NASDAQ: RYTM) reported Q1 EPS of ($0.84), $0.08 worse than the analyst estimate of ($0.76).

Announced updated clinical data from Phase 2 basket study of setmelanotide in MC4R pathway heterozygous (HET) obesity, demonstrating consistent weight and hunger responses in patients with high-impact loss-of-function (LOF) variantsAnnounced strategy for further development in HET obesity with patients stratified into cohorts based on LOF variantTopline data from pivotal... More